RT Journal Article
SR Electronic
T1 Development and Validation of the First FDA Authorized Artificial Intelligence/Machine Learning Diagnostic Tool for the Prediction of Sepsis Risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.06.24306954
DO 10.1101/2024.05.06.24306954
A1 Bhargava, Akhil
A1 López-Espina, Carlos
A1 Schmalz, Lee
A1 Khan, Shah
A1 Watson, Gregory L.
A1 Urdiales, Dennys
A1 Updike, Lincoln
A1 Kurtzman, Niko
A1 Dagan, Alon
A1 Doodlesack, Amanda
A1 Stenson, Bryan A.
A1 Sarma, Deesha
A1 Reseland, Eric
A1 Lee, John H.
A1 Kravitz, Max S.
A1 Antkowiak, Peter S.
A1 Shvilkina, Tatyana
A1 Espinosa, Aimee
A1 Halalau, Alexandra
A1 Demarco, Carmen
A1 Davila, Francisco
A1 Davila, Hugo
A1 Sims, Matthew
A1 Maddens, Nicholas
A1 Berghea, Ramona
A1 Smith, Scott
A1 Palagiri, Ashok V.
A1 Ezekiel, Clinton
A1 Sadaka, Farid
A1 Iyer, Karthik
A1 Crisp, Matthew
A1 Azad, Saleem
A1 Oke, Vikram
A1 Friederich, Andrew
A1 Syed, Anwaruddin
A1 Gosai, Falgun
A1 Chawla, Lavneet
A1 Evans, Neil
A1 Thomas, Kurian
A1 Malkani, Roneil
A1 Patel, Roshni
A1 Mayer, Stockton
A1 Ali, Farhan
A1 Raghavakurup, Lekshminarayan
A1 Tafa, Muleta
A1 Singh, Sahib
A1 Raouf, Samuel
A1 Zhao, Sihai Dave
A1 Zhu, Ruoqing
A1 Bashir, Rashid
A1 Reddy, Bobby
A1 Shapiro, Nathan I.
YR 2024
UL http://medrxiv.org/content/early/2024/08/16/2024.05.06.24306954.abstract
AB Background Sepsis is a life-threatening condition that demands prompt treatment for improved patient outcomes. Its heterogenous presentation makes early detection challenging, highlighting the need for effective risk assessment tools. Artificial Intelligence (AI) models have the potential to accurately identify septic patients, but none have previously been FDA-authorized for commercial use. This study outlines the development and validation of the Sepsis ImmunoScore, the first FDA-authorized AI-based software designed to identify patients at risk of sepsis.Method In this prospective study, adult patients (18+) suspected of infection, as indicated by a blood culture order, were enrolled from five U.S. institutions between April 2017 and July 2022. The participants were divided into an algorithm development cohort (n=2,366), an internal validation cohort (n=393), and an external validation cohort (n=698). The primary endpoint was the presence of sepsis (Sepsis-3) within 24 hours of test initiation. Secondary endpoints included hospital length of stay, ICU admission within 24 hours, mechanical ventilation use within 24 hours, vasopressor use within 24 hours, and in-hospital mortality.Results The Sepsis ImmunoScore demonstrated high diagnostic accuracy, with an AUC of 0.85 (0.83–0.87) in the derivation cohort, 0.80 (0.74–0.86) in internal validation, and 0.81 (0.77– 0.86) in external validation. The score was categorized into four risk levels for sepsis with corresponding likelihood ratios: low (0.1), medium (0.5), high (2.1), and very high (8.3). These risk categories also predicted in-hospital mortality: low (0.0%), medium (1.9%), high (8.7%), and very high (18.2%) in the external validation cohort. Similar trends were observed for other metrics, such as hospital length of stay, ICU utilization, mechanical ventilation, and vasopressor use.Conclusions The Sepsis ImmunoScore demonstrated high accuracy for identification and prediction of sepsis and critical illness that could enable prompt identification of patients at high risk of sepsis and adverse outcomes, potentially improving clinical decision-making and patient outcomes.Description Sepsis is a life-threatening acute condition that requires accurate and rapid identification to guide proper treatment. This study outlines the development and validation of the first FDA-authorized AI-based software to identify patients at risk of having sepsis.Competing Interest StatementConflict of Interest Disclosures: Zhao, Zhu, Shapiro and Bashir are consultants to Prenosis. Bhargava, Lopez-Espina, Schmalz, Khan, Watson, Uridales, Updike, and Reddy. Jr are employed by Prenosis. Bashir and Shapiro have equity ownership in Prenosis, and Bashir has equity interest in VedaBio. Dr. Shapiro is a consultant for Luminos technologies, Cambridge Medical Technologies, and receives research support from Bluejay diagnostics and Inflammatix. Funding StatementFunding/Support: This study was funded in part by the Defense Threat Reduction Agency, National Institutes of Health, Centers for Disease Control and Prevention, National Science Foundation, Biomedical Advanced Research and Development Authority, and Prenosis. Role of the Funder/Sponsor: Prenosis was overall responsible for the design and conduct of the study, collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The other funding agencies had no role.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Beth Israel Deaconess Medical Center waived ethical approval for this work Ethics committee/IRB of Jesse Brown VA Medical Center waived ethical approval for this work Ethics committee/IRB of Mercy Health waived ethical approval for this work Ethics committee/IRB of Beaumont - waived ethical approval for this work Ethics committee/IRB of Carle Foundation Hospital waived ethical approval for this work Ethics committee/IRB of OSF Saint Francis Medical Center partially waived ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are unavailable